Statins are the first-line choice in Lipid-lowering therapy to reduce cardiovascular risk. In a
continuous attempt to optimise treatment success, there is a need for additional research on …

Statins are the first-line treatment for familial hypercholesterolemia (FH), but response is
highly variable due to genetic and nongenetic factors. Here, we explored the association …

HMG-CoA reductase inhibitors (statins) are widely prescribed and recommended as first-line
therapy for most patients with hypercholesterolemia or established coronary heart disease …

Background Patients with dyslipidemia are often treated with statins to reduce lipids and
hence cardiovascular risk, but treatment response is variable, partly due to genetic factors …

Purpose Statins are increasingly widely used in the primary and secondary prevention of
cardiovascular disease. However, there is an inter-individual variation in statin response …

Background—Statins are effective at lowering low-density lipoprotein cholesterol and
reducing risk of cardiovascular disease, but variability in response is not well understood. To …

An increasing number of studies have investigated the association between SLCO1B1−
521T> C and− 388A> G polymorphisms and the risk of statin-induced adverse drug …

Background In addition to lowering low density lipoprotein cholesterol (LDL-C), statin
therapy also raises high density lipoprotein cholesterol (HDL-C) levels. Inter-individual …

Statins form the backbone of lipid‐lowering therapy in the prevention of cardiovascular
disease. Numerous studies have evaluated the effect of genomics on the clinical efficacy …

Objective The SLCO1B1 c. 521T> C polymorphism is associated with statin plasma levels
and simvastatin-induced adverse drug reactions. We studied whether the c. 521T> C …